The future of recombinant coagulation factors

E. L. Saenko*, N. M. Ananyeva, M. Shima, C. A.E. Hauserj, S. W. Pipe

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


Hemophilias A and B are X chromosome-linked bleeding disorders, which are mainly treated by repeated infusions of factor (F)VIII or FIX, respectively. In the present review, we specify the limitations in expression of recombinant (r)FVIII and summarize the bioengineering strategies that are currently being explored for constructing novel rFVIII molecules characterized by high efficiency expression and improved functional properties. We present the strategy to prolong FVIII lifetime by disrupting FVIII interaction with its clearance receptors and demonstrate how construction of human-porcine FVIII hybrid molecules can reduce their reactivity towards inhibitory antibodies. While the progress in improving rFIX is impeded by low recovery rates, the authors are optimistic that the efforts of basic science may ultimately lead to higher efficiency of replacement therapy of both hemophilias A and B.

Original languageEnglish (US)
Pages (from-to)922-930
Number of pages9
JournalJournal of Thrombosis and Haemostasis
Issue number5
StatePublished - May 2003
Externally publishedYes


  • Bioengineering
  • Hemophilia
  • Recombinant factor IX
  • Recombinant factor VIII
  • Replacement therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The future of recombinant coagulation factors'. Together they form a unique fingerprint.

Cite this